Bruker Says 'Material Weakness' at Subsidiary
Will Force Firm to Raise 2004 Losses

A "material weakness in internal controls" at an undisclosed Bruker BioSciences subsidiary will cause Bruker to increase its 2004 net losses, the company said.

According to a statement released Wednesday, Bruker said it has been made aware of several 2004 audit adjustments that it said will have a negative impact on its 2004 financial results.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers test gene therapy targeting a different cancer protein in a new trial, the New York Times reports.

Pennsylvania State University researchers found that salivary microRNAs could predict which kids would have longer concussion symptoms, according to NPR.

The Associated Press reports Alex Azar, the new Department of Health and Human Services secretary nominee, made millions of dollars as a pharmaceutical executive.

In PNAS this week: immune profiling of breast cancer, transposable element patterns in rice, and more.